Abstract
Immuno-oncologic therapies have been approved to treat variety of cancer types and have significantly improved quality of life and overall survival of all patients. For SCCHN, nivolumab and pembrolizumab are approved after platinum-based chemotherapy. Decision makers are developing cost-effectiveness of IO therapies. This study is a targeted review of published CEA models and understand the variations in model specifications and results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
